Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Anal Bioanal Chem. 2018 Aug 3;410(23):6009–6029. doi: 10.1007/s00216-018-1222-4

Table 2.

Recovery of targeted oxylipins from quality control samples at five different concentration levels (n = 3 or 4)

Compound LQC2 (0.5 ng/mL)* LQC2 (0.5 ng/mL)* QC3 (1 ng/mL)* QC4 (10 ng/mL)* QC5 (80 ng/mL)*
PMC Plasma Plasma PMC Plasma PMC Plasma PMC Plasma
RC RSD% RC RSD% RC RSD% RC RSD% RC RSD% RC RSD% RC RSD% RC RSD% RC RSD%
9-HODE 98.4 1.8 89.8 15.1 93.3 13.4 98.9 12.4 95.1 7.7 93.4 5.6 99.6 10.5 102.6 4.6 88.4 4.8
13-HODE NQ NA NQ NA 97.3 11.0 103.5 6.8 99.9 14.5 94.9 7.8 104.0 4.1 103.7 7.5 87.1 9.3
9-oxoODE 109.5 17.0 87.3 8.2 95.9 7.7 102.8 15.7 99.4 9.8 99.3 2.2 101.7 11.9 103.9 11.7 80.8 14.3
13-oxoODE 90.1 21.9 103.2 10.9 99.6 11.1 101.7 14.0 89.6 15.1 98.1 3.7 100.0 10.1 104.6 11.5 82.0 11.0
9,10-EpOME NQ NA NQ NA NQ NA 96.0 7.9 114.2 19.2 92.5 2.6 101.7 12.7 104.1 8.8 86.0 4.0
12,13-EPOME NQ NA NQ NA NQ NA 99.4 15.2 101.9 13.4 91.9 2.9 100.0 18.1 103.0 10.4 83.8 8.3
9,10-DiHOME 102.7 4.6 82.4 12.9 90.7 10.4 102.6 7.3 94.6 4.9 100.9 7.2 97.7 13.5 107.9 3.8 88.9 10.2
12,13-DiHOME 99.8 7.4 90.3 12.6 73.3 12.0 101.3 10.7 90.1 6.8 99.8 5.6 99.6 15.0 108.6 6.3 88.1 7.5
9,12,13-TriHOME NQ NA NQ NA NQ NA 100.8 2.5 112.6 13.9 100.4 3.2 102.6 13.1 105.5 8.1 89.1 11.0
9,10,13-TriHOME NQ NA NQ NA 100.4 9.9 101.0 7.4 100.7 9.2 99.5 4.0 101.0 12.3 104.9 6.0 90.7 9.9
9,10,11-TriHOME 116.2 8.3 97.0 10.6 98.6 11.4 96.5 5.0 94.8 14.1 99.8 5.4 100.0 11.0 105.0 11.0 90.8 12.9
9-HOTrE 96.3 1.6 97.1 5.7 95.4 7.1 102.4 10.9 98.2 11.0 96.8 10.0 99.0 7.8 103.3 7.1 88.9 4.2
13-HOTrE 107.0 3.4 79.8 25.5 85.6 5.1 101.1 14.8 98.1 9.4 96.8 7.1 99.8 12.1 106.1 6.7 84.9 12.1
PGE2 102.4 10.7 92.5 14.0 104.9 6.7 107.9 6.7 97.1 13.8 104.5 9.3 100.9 7.0 113.4 7.7 93.1 10.1
PGF NQ NA NQ NA NQ NA 103.7 8.5 92.9 7.5 99.0 8.9 98.1 8.1 104.8 8.9 89.1 13.1
8-IsoPGF NQ NA NQ NA 104.6 12.3 107.7 6.0 94.8 10.7 100.6 6.7 101.6 10.4 105.2 8.2 89.4 12.7
TXB2 95.6 4.7 102.5 5.2 97.0 4.0 101.8 9.3 95.1 12.0 99.8 4.4 97.4 13.6 103.5 13.7 89.4 12.6
LTB4 90.7 5.1 110.4 10.4 94.4 10.4 100.2 9.0 96.4 5.4 97.1 2.7 97.3 13.0 104.7 7.7 85.8 13.9
LXA4 98.6 9.6 69.6 7.4 92.1 6.3 102.8 9.7 93.8 6.3 97.4 6.5 98.3 9.6 107.5 7.6 87.9 14.9
LXB4 104.1 13.3 NQ NA 98.8 10.8 102.6 8.9 96.9 2.1 99.0 5.5 98.9 8.5 104.2 6.2 87.9 15.0
5-HETE 86.4 4.2 85.1 13.5 92.3 1.8 89.0 11.5 96.2 12.4 86.7 2.0 98.3 10.3 97.4 8.9 84.1 12.5
8-HETE 96.5 7.6 104.3 12.1 92.6 7.0 89.5 8.3 90.6 7.9 87.9 4.9 98.2 9.4 100.9 12.9 81.2 12.8
9-HETE 93.5 13.0 91.9 11.7 94.9 8.6 97.0 7.8 95.1 13.1 89.0 6.8 99.6 10.3 99.4 14.1 83.3 7.0
11-HETE 94.1 1.9 100.1 9.8 92.7 10.5 92.9 11.7 95.2 11.1 89.7 2.4 99.3 12.6 102.1 12.1 85.0 9.5
12-HETE 90.9 15.6 88.2 13.9 85.7 5.7 96.4 12.5 96.1 12.0 94.5 3.0 99.1 9.2 101.6 11.7 81.6 12.0
15-HETE 96.2 9.6 95.3 17.9 96.9 9.7 89.6 14.8 101.1 6.7 92.0 4.3 102.4 7.7 104.0 12.9 84.9 11.7
20-HETE 121.2 21.8 86.7 10.7 96.7 9.4 103.0 12.8 103.6 17.4 94.0 12.2 103.6 3.0 104.0 11.2 83.6 15.6
5-oxoETE 85.2 10.2 87.4 12.7 95.5 8.5 86.3 12.7 97.2 12.1 99.0 11.2 96.5 18.5 99.9 7.8 88.8 10.8
5,6-EET 38.3 13.4 61.3 11.7 43.4 5.1 66.2 7.9 53.1 13.8 63.3 13.8
8.9-EET 89.3 5.0 89.8 9.6 97.3 8.8 86.9 7.4 97.0 10.1 83.0 2.9 97.4 12.2 95.8 10.2 79.3 11.6
11,12-EET 82.3 12.0 94.4 4.8 91.6 6.9 91.5 5.1 93.7 5.8 81.9 4.7 95.6 10.7 96.0 9.4 81.6 11.8
14,15-EET 92.1 7.4 93.7 3.0 97.9 5.7 92.0 13.2 92.7 5.8 90.9 6.9 99.7 12.0 99.5 5.7 86.1 12.6
18-HEPE 98.6 7.6 99.8 6.3 92.4 6.1 98.0 12.1 98.2 10.7 95.3 6.4 98.5 11.3 101.9 7.3 84.8 10.6
14,15-EEQ 93.6 4.9 92.3 7.9 93.6 7.7 95.8 7.9 92.0 9.5 91.7 5.9 100.5 11.3 103.1 12.7 82.7 10.9
17,18-EEQ 103.8 5.8 103.8 11.1 91.8 8.1 104.6 14.1 96.8 5.8 94.8 2.7 100.4 9.2 104.6 11.9 80.4 14.8
4-HDHA 87.8 5.5 109.5 15.4 92.3 10.7 86.3 10.9 96.3 6.5 77.7 2.7 95.5 10.7 90.7 13.5 83.6 10.6
7-HDHA 101.0 9.8 99.5 7.2 95.7 5.9 94.6 6.7 97.2 13.6 86.0 5.9 98.3 11.3 97.7 11.5 83.4 11.5
10-HDHA 88.2 6.8 95.2 6.2 91.6 14.6 86.0 6.9 97.5 13.6 88.2 5.4 98.3 10.4 98.8 13.2 83.0 10.8
14-HDHA 106.7 17.8 92.5 17.4 93.2 7.2 90.5 11.4 99.4 9.7 85.1 4.9 98.3 12.6 98.3 12.5 82.2 12.7
17-HDHA 93.8 14.1 73.7 11.4 88.1 12.7 99.5 8.9 104.2 11.8 88.3 2.1 104.1 7.7 98.4 11.9 86.3 12.7
PDX 97.9 6.3 100.8 10.2 96.1 8.9 98.0 11.3 96.7 4.5 96.5 3.9 98.7 12.1 107.0 9.9 85.9 12.3
MaR1 89.2 5.7 93.4 2.3 91.0 4.9 100.3 13.7 95.4 5.5 96.2 6.3 96.1 11.3 107.1 7.9 86.8 12.1
RvD1 92.4 8.8 72.1 4.8 93.2 10.1 98.8 15.7 87.3 11.3 101.6 4.0 100.0 7.3 103.0 9.6 90.8 5.3
RvD2 NQ NA NQ NA 97.2 14.3 87.9 15.0 100.0 5.5 98.5 6.6 97.4 7.7 102.1 7.7 88.4 13.3
16,17-EDP 86.4 7.9 88.5 13.7 82.9 9.2 81.9 7.2 103.3 15.0 84.6 4.0 101.3 15.8 94.6 11.5 80.5 9.9
19,20-EDP 91.6 8.3 97.4 10.8 87.1 8.2 81.2 12.1 99.1 6.8 83.4 5.1 98.3 10.9 96.1 10.3 79.5 14.1
11-H-9-E-LA NQ NA NQ NA 99.3 16.1 92.4 13.9 80.1 17.2 101.3 6.6 100.3 14.0 108.4 8.1 87.8 12.8
13-H-9-E-LA 104.7 17.7 91.0 9.7 91.7 14.9 91.0 20.0 94.6 8.4 102.1 7.2 98.5 13.5 107.1 10.2 86.9 13.1
9-H-12-E-LA 111.8 7.4 99.3 11.4 86.2 14.2 94.4 18.3 92.3 8.4 102.4 5.0 96.0 12.3 108.4 7.4 86.7 14.5
11-H-12-E-LA NQ NA NQ NA NQ NA 71.3 20.3 66.8 10.4 104.3 4.7 95.0 13.6 107.8 8.6 92.0 14.0

Recoveries (RC) of oxylipins were evaluated using four or five spiked concentrations for PMC and plasma, respectively, and oxylipin levels in plasma were adjusted for endogenous level subtraction. Experimental details in Section 1.9.5. For EHODEs and EKODEs with two or three peaks, recoveries were determined by sum of each peaks in Excel. NQ: the concentration is below the LOQ or out of the linear range or not detected, NA: not available,

*

: for 9-HODE and 9-HOTrE, concentration levels of QC1, QC2, QC3, QC4, and QC5 were 2, 5, 10,100, and 800, respectively. Experimental details in Recovery Section under Method